1. India Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Brooks Laboratories Limited

Brooks Laboratories Limited

BROOKS.BO
Brooks Laboratories LimitedIN flagBombay Stock Exchange
76.99
INR
-0.72
- -
2.28BMarket Cap

Total Valuation

Brooks Laboratories Limited carries a market capitalization of 2.28B, placing it among publicly traded companies globally. Its enterprise value stands at 1.11B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap2.28B
Enterprise Value1.11B

Share Statistics

Brooks Laboratories Limited currently has 29.46M shares outstanding.

Shares Outstanding29.46M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

Brooks Laboratories Limited trades at a trailing price-to-earnings ratio of 4.48. The price-to-sales ratio is 1.29, and the price-to-book ratio stands at 3.74.

PE Ratio4.48
PS Ratio1.29
PB Ratio3.74
P/TBV Ratio0.90
P/FCF RatioN/A
P/OCF RatioN/A

Enterprise Valuation

On an enterprise value basis, Brooks Laboratories Limited trades at an EV/EBITDA multiple of 20.28 and an EV/FCF ratio of 132.77. The EV/Sales ratio of 1.29 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 20.28 provides insight into valuation relative to core operating earnings.

EV / Sales1.29
EV / EBITDA20.28
EV / EBIT20.28
EV / FCF132.77

Financial Position

Brooks Laboratories Limited maintains a current ratio of 1.72, meaning it holds 1.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 6.94, indicating elevated leverage, while an interest coverage ratio of 6.55 demonstrates adequate ability to service its debt obligations.

Current Ratio1.72
Quick Ratio0.36
Debt / Equity6.94
Debt / EBITDA1.56
Interest Coverage6.55

Financial Efficiency

Brooks Laboratories Limited posts a return on equity of 50.16 and a return on invested capital of 4.62.

Return on Equity (ROE)50.16
Return on Assets (ROA)18.08
Return on Invested Capital (ROIC)4.62
Return on Capital Employed (ROCE)192.84
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover5.04

Stock Price Statistics

Brooks Laboratories Limited's stock has declined approximately -45.10517% over the past 52 weeks. The 50-day moving average sits at 62.29, while the 200-day moving average is 81.14.

Beta (5Y)N/A
52-Week Price Change-45.10517%
50-Day Moving Average62.29
200-Day Moving Average81.14
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, Brooks Laboratories Limited generated 857.38M in revenue and converted that into 245.84M in net income, yielding earnings per share of 8.36. EBITDA reached 54.70M, while operating income came in at 54.70M.

Revenue857.38M
Gross Profit347.17M
Operating Income54.70M
Pretax Income245.84M
Net Income245.84M
EBITDA54.70M
EBIT54.70M
Earnings Per Share (EPS)8.36

Balance Sheet

Brooks Laboratories Limited holds 78.53M in cash and equivalents against 85.17M in total debt, resulting in a net debt position of 6.90M. Total book value stands at 294.57M, with working capital of 156.01M providing operational flexibility.

Cash & Cash Equivalents78.53M
Total Debt85.17M
Net Debt6.90M
Equity (Book Value)294.57M
Book Value Per Share10.02
Working Capital156.01M

Margins

Brooks Laboratories Limited operates with a gross margin of 40.49, reflecting its pricing power and cost economics. The operating margin of 6.38 and net profit margin of 28.67 provide insight into operational efficiency.

Gross Margin40.49
Operating Margin6.38
Pretax Margin28.67
Profit Margin28.67
EBITDA Margin6.38

Stock Splits

Brooks Laboratories Limited's most recent stock split took place on February 11, 2020 with a 1000:1199 split ratio.

Last Split Date2/11/2020
Split Ratio1000:1199

Scores

Brooks Laboratories Limited posts an Altman Z-Score of 3.42, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score3.42